Floatz logo

Carboplatin

Uterine Carcinosarcoma

GOG FoundationSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Uterine Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Ifosfamide
GOG Foundation
Phase 3B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
Niraparib
ARCAGY/ GINECO GROUP
Phase 2/3B
Dostarlimab
ARCAGY/ GINECO GROUP
Phase 2/3B

View all 14 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →